 |
Monica Heger tracks trends in next-generation sequencing for research and clinical applications for GenomeWeb's In Sequence and Clinical Sequencing News. E-mail Monica Heger or follow her GenomeWeb Twitter accounts at @InSequence and @ClinSeqNews. |
Illumina Says BlueGnome Buy is Step Toward Broader Cytogenetics Strategy Based on Arrays, Sequencing
September 19, 2012
Illumina Says BlueGnome Buy is Step Toward Broader Cytogenetics Strategy Based on Arrays, Sequencing
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- NIPT and Cancer Drive Illumina's Clinical Business in Q1 as it Looks to Launch Fetal Aneuploidy IVD
April 24, 2013 / Clinical Sequencing News - Illumina Plans to Submit MiSeqDx Assays for Cystic Fibrosis to FDA this Year
November 1, 2012 / Clinical Sequencing News - Expanding Clinical and Dx Business, Illumina Plans to Hire Associate Director of Medical Affairs
September 5, 2012 / Clinical Sequencing News - Illumina Sees Growing Commercial Customer Base; Doubled Clinical HiSeq Placements in 2011
February 8, 2012 / Clinical Sequencing News - Siemens Sees Opportunity for NGS in Clinical Dx as it Transitions HIV Assay to MiSeq
November 9, 2011 / Clinical Sequencing News